TapewireFind a company

person · Reporting owner

Mills Kenneth T.

Disclosed activity across 1 company

Tapewire entity
42388
SEC CIK
0001652824

Export transaction history ↓

Reported relationships

Latest disclosed role at each company.

CompanyLast reported asReport datePublished
REGENXBIO Inc.RGNX · Entity 2211DirectorMay 29, 2026June 02, 2026

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

REGENXBIO Inc.

Report date May 29, 2026 · Filed June 02, 2026

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Common StockSEC Table I · non-derivativeDirect495,925 Reported balance After 2026-05-29 transaction · row 1
1 source row

Row 1 · 2026-05-29 · Grant · Acquired 9,807 · Balance 495,925

F1: Represents shares of common stock underlying a time-based restricted stock unit award (RSU). 100% of the shares subject to this RSU will vest on May 29, 2027 subject to the continuous service of the recipient to the Issuer.

Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $7.01 · Expires 2036-05-29Direct46,600 Reported balance After 2026-05-29 transaction · row 2 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 2 · 2026-05-29 · Grant · Acquired 46,600 · Balance 46,600

F2: The option will vest May 29, 2027 subject to the continuous service of the optionee to the Issuer.

Filing footnotes · ownership attribution and instrument terms

F1: Represents shares of common stock underlying a time-based restricted stock unit award (RSU). 100% of the shares subject to this RSU will vest on May 29, 2027 subject to the continuous service of the recipient to the Issuer.

F2: The option will vest May 29, 2027 subject to the continuous service of the optionee to the Issuer.

Transaction history

JSON API
Reset

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction dateCompanyActivity / securityShares / unitsReported priceReported valueDetails
May 29, 2026 Filed Jun 2, 2026 21:16 UTC REGENXBIO Inc. RGNX · Entity 2211 GrantStock Options (Right to Buy) · Derivative 46,600 $0.00 Strike: $7.01 $0.00
Disclosure

SEC source: 0001652824-26-000003 · primarydocument.xml · derivative · entry 2

Mills Kenneth T. · CIK 0001652824 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 46,600

Underlying: Common Stock · 46,600 shares

Expires 2036-05-29

F2 · derivative.exercise_date: The option will vest May 29, 2027 subject to the continuous service of the optionee to the Issuer.

Read SEC document
May 29, 2026 Filed Jun 2, 2026 21:16 UTC REGENXBIO Inc. RGNX · Entity 2211 GrantCommon Stock 9,807 $0.00 $0.00
Disclosure

SEC source: 0001652824-26-000003 · primarydocument.xml · nonDerivative · entry 1

Mills Kenneth T. · CIK 0001652824 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 495,925

F1 · shares: Represents shares of common stock underlying a time-based restricted stock unit award (RSU). 100% of the shares subject to this RSU will vest on May 29, 2027 subject to the continuous service of the recipient to the Issuer.

Read SEC document
January 27, 2026 Filed Jan 29, 2026 21:58 UTC REGENXBIO Inc. RGNX · Entity 2211 Exercise / conversionStock Options (Right to Buy) · Derivative 225,000 $0.00 Strike: $13.09 $0.00
Disclosure

SEC source: 0001652824-26-000002 · primarydocument.xml · derivative · entry 3

Mills Kenneth T. · CIK 0001652824 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 225,000

Underlying: Common Stock · 225,000 shares

Expires 2026-01-28

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_date: The previously granted option, representing a right to purchase a total of 225,000 shares, became exercisable as follows: 25% of the shares subject to this option vested on January 28, 2017, and the balance vested in equal monthly installments over the 36 months thereafter.

Read SEC document
January 27, 2026 Filed Jan 29, 2026 21:58 UTC REGENXBIO Inc. RGNX · Entity 2211 Tax withholdingCommon Stock 221,753 $13.41 $2,973,707.73
Disclosure

SEC source: 0001652824-26-000002 · primarydocument.xml · nonDerivative · entry 2

Mills Kenneth T. · CIK 0001652824 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 486,118

F2 · kind: Represents shares of common stock withheld to satisfy the exercise price and pay taxes upon the exercise of options originally granted to the reporting person on January 28, 2016, which were set to expire on January 28, 2026. The number of shares withheld was determined based on the closing price of the issuer's common stock on January 27, 2026. The transaction did not involve any open-market sale of securities.

Read SEC document
January 27, 2026 Filed Jan 29, 2026 21:58 UTC REGENXBIO Inc. RGNX · Entity 2211 Exercise / conversionCommon Stock 225,000 $13.09 $2,945,250.00
Disclosure

SEC source: 0001652824-26-000002 · primarydocument.xml · nonDerivative · entry 1

Mills Kenneth T. · CIK 0001652824 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 707,871

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The previously granted option, representing a right to purchase a total of 225,000 shares, became exercisable as follows: 25% of the shares subject to this option vested on January 28, 2017, and the balance vested in equal monthly installments over the 36 months thereafter.

Read SEC document
May 30, 2025 Filed Jun 3, 2025 20:32 UTC REGENXBIO Inc. RGNX · Entity 2211 GrantStock Options (Right to Buy) · Derivative 39,815 $0.00 Strike: $8.85 $0.00
Disclosure

SEC source: 0001562180-25-004351 · primarydocument.xml · derivative · entry 2

Mills Kenneth T. · CIK 0001652824 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 39,815

Underlying: Common Stock · 39,815 shares

Expires 2035-05-30

F2 · derivative.exercise_date: The option will vest in 12 equal monthly installments following May 30, 2025 subject to the continuous service of the optionee to the Issuer.

Read SEC document
May 30, 2025 Filed Jun 3, 2025 20:32 UTC REGENXBIO Inc. RGNX · Entity 2211 GrantCommon Stock 7,768 $0.00 $0.00
Disclosure

SEC source: 0001562180-25-004351 · primarydocument.xml · nonDerivative · entry 1

Mills Kenneth T. · CIK 0001652824 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 482,871

F1 · shares: Represents shares of common stock underlying a time-based restricted stock unit award (RSU). 100% of the shares subject to this RSU will vest on May 1, 2026 subject to the continuous service of the recipient to the Issuer.

Read SEC document
May 12, 2025 Filed May 14, 2025 20:49 UTC REGENXBIO Inc. RGNX · Entity 2211 Exercise / conversionStock Options (Right to Buy) · Derivative 20,602 $0.00 Strike: $3.76 $0.00
Disclosure

SEC source: 0001562180-25-003822 · primarydocument.xml · derivative · entry 3

Mills Kenneth T. · CIK 0001652824 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 20,602 shares

Expires 2025-05-19

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan.

F3 · derivative.exercise_date: The previously granted option, representing a right to purchase a total of 275,000 shares, became exercisable as follows: 25% of the shares subject to this option vested on May 19, 2016, and the balance vested in equal monthly installments over the 36 months thereafter.

Read SEC document
May 12, 2025 Filed May 14, 2025 20:49 UTC REGENXBIO Inc. RGNX · Entity 2211 SaleCommon Stock 20,602 $7.91 $163,046.29
Disclosure

SEC source: 0001562180-25-003822 · primarydocument.xml · nonDerivative · entry 2

Mills Kenneth T. · CIK 0001652824 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 475,103

F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan.

F2 · price: This transaction was executed in multiple trades at prices ranging from $7.66 to $8.04. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

Read SEC document
May 12, 2025 Filed May 14, 2025 20:49 UTC REGENXBIO Inc. RGNX · Entity 2211 Exercise / conversionCommon Stock 20,602 $3.76 $77,463.52
Disclosure

SEC source: 0001562180-25-003822 · primarydocument.xml · nonDerivative · entry 1

Mills Kenneth T. · CIK 0001652824 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 495,705

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan.

Read SEC document
March 27, 2025 Filed Mar 31, 2025 21:05 UTC REGENXBIO Inc. RGNX · Entity 2211 Exercise / conversionStock Options (Right to Buy) · Derivative 30,752 $0.00 Strike: $3.76 $0.00
Disclosure

SEC source: 0001562180-25-002804 · primarydocument.xml · derivative · entry 2

Mills Kenneth T. · CIK 0001652824 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 20,602

Underlying: Common Stock · 30,752 shares

Expires 2025-05-19

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_date: The previously granted option, representing a right to purchase a total of 275,000 shares, became exercisable as follows: 25% of the shares subject to this option vested on May 19, 2016, and the balance vested in equal monthly installments over the 36 months thereafter.

Read SEC document
March 27, 2025 Filed Mar 31, 2025 21:05 UTC REGENXBIO Inc. RGNX · Entity 2211 Exercise / conversionCommon Stock 30,752 $3.76 $115,627.52
Disclosure

SEC source: 0001562180-25-002804 · primarydocument.xml · nonDerivative · entry 1

Mills Kenneth T. · CIK 0001652824 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 475,103

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The previously granted option, representing a right to purchase a total of 275,000 shares, became exercisable as follows: 25% of the shares subject to this option vested on May 19, 2016, and the balance vested in equal monthly installments over the 36 months thereafter.

Read SEC document
August 08, 2024 Filed Aug 12, 2024 20:58 UTC REGENXBIO Inc. RGNX · Entity 2211 Exercise / conversionStock Options (Right to Buy) · Derivative 36,316 $0.00 Strike: $0.85 $0.00
Disclosure

SEC source: 0001562180-24-006146 · primarydocument.xml · derivative · entry 2

Mills Kenneth T. · CIK 0001652824 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 36,316 shares

Expires 2024-09-24

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_date: The previously granted option, representing a right to purchase a total of 708,200 shares, became exercisable as follows: 474,490 of the shares subject to the option are initial shares ("Initial Shares") and 233,710 of the shares subject to the option are contingent shares ("Contingent Shares"). 120,394 of the Initial Shares vested on September 17, 2014, 88,524 of the Initial Shares vested on September 17, 2015 and an additional 7,377 of the Initial Shares vested upon each month of continuous service to the Company thereafter. 25% of the Contingent Shares were deemed vested as of September 17, 2014 on January 13, 2015 due to a subsequent event. The remainder of the Contingent Shares vested over four years of service following September 17, 2014, with 25% of the remaining 75% of Contingent Shares having vested on September 17, 2015 and the remaining Contingent Shares having vested in 36 equal monthly installments thereafter.

Read SEC document
August 08, 2024 Filed Aug 12, 2024 20:58 UTC REGENXBIO Inc. RGNX · Entity 2211 Exercise / conversionCommon Stock 36,316 $0.85 $30,868.60
Disclosure

SEC source: 0001562180-24-006146 · primarydocument.xml · nonDerivative · entry 1

Mills Kenneth T. · CIK 0001652824 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 444,351

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

Read SEC document
July 25, 2024 Filed Jul 26, 2024 21:00 UTC REGENXBIO Inc. RGNX · Entity 2211 Exercise / conversionStock Options (Right to Buy) · Derivative 15,369 $0.00 Strike: $3.76 $0.00
Disclosure

SEC source: 0001562180-24-005855 · primarydocument.xml · derivative · entry 6

Mills Kenneth T. · CIK 0001652824 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 51,354

Underlying: Common Stock · 15,369 shares

Expires 2025-05-19

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F4 · derivative.exercise_date: The previously granted option, representing a right to purchase a total of 275,000 shares, became exercisable as follows: 25% of the shares subject to this option vested on May 19, 2016, and the balance vested in equal monthly installments over the 36 months thereafter.

Read SEC document
July 25, 2024 Filed Jul 26, 2024 21:00 UTC REGENXBIO Inc. RGNX · Entity 2211 SaleCommon Stock 15,369 $13.96 $214,500.52
Disclosure

SEC source: 0001562180-24-005855 · primarydocument.xml · nonDerivative · entry 4

Mills Kenneth T. · CIK 0001652824 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 408,035

F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan.

F3 · price: This transaction was executed in multiple trades at prices ranging from $13.76 to $14.25. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

Read SEC document
July 25, 2024 Filed Jul 26, 2024 21:00 UTC REGENXBIO Inc. RGNX · Entity 2211 Exercise / conversionCommon Stock 15,369 $3.76 $57,787.44
Disclosure

SEC source: 0001562180-24-005855 · primarydocument.xml · nonDerivative · entry 3

Mills Kenneth T. · CIK 0001652824 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 423,404

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan.

Read SEC document
July 24, 2024 Filed Jul 26, 2024 21:00 UTC REGENXBIO Inc. RGNX · Entity 2211 Exercise / conversionStock Options (Right to Buy) · Derivative 12,221 $0.00 Strike: $3.76 $0.00
Disclosure

SEC source: 0001562180-24-005855 · primarydocument.xml · derivative · entry 5

Mills Kenneth T. · CIK 0001652824 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 66,723

Underlying: Common Stock · 12,221 shares

Expires 2025-05-19

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan.

F4 · derivative.exercise_date: The previously granted option, representing a right to purchase a total of 275,000 shares, became exercisable as follows: 25% of the shares subject to this option vested on May 19, 2016, and the balance vested in equal monthly installments over the 36 months thereafter.

Read SEC document
July 24, 2024 Filed Jul 26, 2024 21:00 UTC REGENXBIO Inc. RGNX · Entity 2211 SaleCommon Stock 12,221 $13.78 $168,433.49
Disclosure

SEC source: 0001562180-24-005855 · primarydocument.xml · nonDerivative · entry 2

Mills Kenneth T. · CIK 0001652824 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 408,035

F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan.

F2 · price: This transaction was executed in multiple trades at prices ranging from $13.76 to $13.85. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

Read SEC document
July 24, 2024 Filed Jul 26, 2024 21:00 UTC REGENXBIO Inc. RGNX · Entity 2211 Exercise / conversionCommon Stock 12,221 $3.76 $45,950.96
Disclosure

SEC source: 0001562180-24-005855 · primarydocument.xml · nonDerivative · entry 1

Mills Kenneth T. · CIK 0001652824 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 420,256

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan.

Read SEC document
July 17, 2024 Filed Jul 18, 2024 21:05 UTC REGENXBIO Inc. RGNX · Entity 2211 Exercise / conversionStock Options (Right to Buy) · Derivative 2,210 $0.00 Strike: $3.76 $0.00
Disclosure

SEC source: 0001562180-24-005798 · primarydocument.xml · derivative · entry 6

Mills Kenneth T. · CIK 0001652824 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 78,944

Underlying: Common Stock · 2,210 shares

Expires 2025-05-19

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan.

F3 · derivative.exercise_date: The previously granted option, representing a right to purchase a total of 275,000 shares, became exercisable as follows: 25% of the shares subject to this option vested on May 19, 2016, and the balance vested in equal monthly installments over the 36 months thereafter.

Read SEC document
July 17, 2024 Filed Jul 18, 2024 21:05 UTC REGENXBIO Inc. RGNX · Entity 2211 SaleCommon Stock 2,210 $13.77 $30,439.88
Disclosure

SEC source: 0001562180-24-005798 · primarydocument.xml · nonDerivative · entry 4

Mills Kenneth T. · CIK 0001652824 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 408,035

F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan.

F2 · price: This transaction was executed in multiple trades at prices ranging from $13.76 to $13.80. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

Read SEC document
July 17, 2024 Filed Jul 18, 2024 21:05 UTC REGENXBIO Inc. RGNX · Entity 2211 Exercise / conversionCommon Stock 2,210 $3.76 $8,309.60
Disclosure

SEC source: 0001562180-24-005798 · primarydocument.xml · nonDerivative · entry 3

Mills Kenneth T. · CIK 0001652824 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 410,245

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan.

Read SEC document
July 16, 2024 Filed Jul 18, 2024 21:05 UTC REGENXBIO Inc. RGNX · Entity 2211 Exercise / conversionStock Options (Right to Buy) · Derivative 200 $0.00 Strike: $3.76 $0.00
Disclosure

SEC source: 0001562180-24-005798 · primarydocument.xml · derivative · entry 5

Mills Kenneth T. · CIK 0001652824 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 81,154

Underlying: Common Stock · 200 shares

Expires 2025-05-19

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan.

F3 · derivative.exercise_date: The previously granted option, representing a right to purchase a total of 275,000 shares, became exercisable as follows: 25% of the shares subject to this option vested on May 19, 2016, and the balance vested in equal monthly installments over the 36 months thereafter.

Read SEC document
July 16, 2024 Filed Jul 18, 2024 21:05 UTC REGENXBIO Inc. RGNX · Entity 2211 SaleCommon Stock 200 $13.76 $2,752.00
Disclosure

SEC source: 0001562180-24-005798 · primarydocument.xml · nonDerivative · entry 2

Mills Kenneth T. · CIK 0001652824 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 408,035

F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan.

Read SEC document
July 16, 2024 Filed Jul 18, 2024 21:05 UTC REGENXBIO Inc. RGNX · Entity 2211 Exercise / conversionCommon Stock 200 $3.76 $752.00
Disclosure

SEC source: 0001562180-24-005798 · primarydocument.xml · nonDerivative · entry 1

Mills Kenneth T. · CIK 0001652824 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 408,235

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan.

Read SEC document
May 14, 2024 Filed May 16, 2024 21:06 UTC REGENXBIO Inc. RGNX · Entity 2211 Exercise / conversionStock Options (Right to Buy) · Derivative 15,000 $0.00 Strike: $3.76 $0.00
Disclosure

SEC source: 0001562180-24-004104 · primarydocument.xml · derivative · entry 3

Mills Kenneth T. · CIK 0001652824 · Director · President and CEO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 81,354

Underlying: Common Stock · 15,000 shares

Expires 2025-05-19

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan.

F3 · derivative.exercise_date: The previously granted option, which expires on May 19, 2025, representing a right to purchase a total of 275,000 shares, became exercisable as follows: 25% of the shares subject to this option vested on May 19, 2016, and the balance vested in equal monthly installments over the 36 months thereafter.

Read SEC document
May 14, 2024 Filed May 16, 2024 21:06 UTC REGENXBIO Inc. RGNX · Entity 2211 SaleCommon Stock 15,000 $15.81 $237,222.00
Disclosure

SEC source: 0001562180-24-004104 · primarydocument.xml · nonDerivative · entry 2

Mills Kenneth T. · CIK 0001652824 · Director · President and CEO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 408,035

F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan.

F2 · price: This transaction was executed in multiple trades at prices ranging from $15.59 to $16.25. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

Read SEC document
May 14, 2024 Filed May 16, 2024 21:06 UTC REGENXBIO Inc. RGNX · Entity 2211 Exercise / conversionCommon Stock 15,000 $3.76 $56,400.00
Disclosure

SEC source: 0001562180-24-004104 · primarydocument.xml · nonDerivative · entry 1

Mills Kenneth T. · CIK 0001652824 · Director · President and CEO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 423,035

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan.

Read SEC document
April 15, 2024 Filed Apr 17, 2024 21:05 UTC REGENXBIO Inc. RGNX · Entity 2211 Exercise / conversionStock Options (Right to Buy) · Derivative 15,000 $0.00 Strike: $3.76 $0.00
Disclosure

SEC source: 0001562180-24-003452 · primarydocument.xml · derivative · entry 3

Mills Kenneth T. · CIK 0001652824 · Director · President and CEO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 96,354

Underlying: Common Stock · 15,000 shares

Expires 2025-05-19

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan.

F3 · derivative.exercise_date: The previously granted option, which expires on May 19, 2025, representing a right to purchase a total of 275,000 shares, became exercisable as follows: 25% of the shares subject to this option vested on May 19, 2016, and the balance vested in equal monthly installments over the 36 months thereafter.

Read SEC document
April 15, 2024 Filed Apr 17, 2024 21:05 UTC REGENXBIO Inc. RGNX · Entity 2211 SaleCommon Stock 15,000 $18.19 $272,871.00
Disclosure

SEC source: 0001562180-24-003452 · primarydocument.xml · nonDerivative · entry 2

Mills Kenneth T. · CIK 0001652824 · Director · President and CEO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 408,035

F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan.

F2 · price: This transaction was executed in multiple trades at prices ranging from $17.82 to $18.61. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

Read SEC document
April 15, 2024 Filed Apr 17, 2024 21:05 UTC REGENXBIO Inc. RGNX · Entity 2211 Exercise / conversionCommon Stock 15,000 $3.76 $56,400.00
Disclosure

SEC source: 0001562180-24-003452 · primarydocument.xml · nonDerivative · entry 1

Mills Kenneth T. · CIK 0001652824 · Director · President and CEO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 423,035

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan.

Read SEC document
March 14, 2024 Filed Mar 18, 2024 21:03 UTC REGENXBIO Inc. RGNX · Entity 2211 Exercise / conversionStock Options (Right to Buy) · Derivative 15,000 $0.00 Strike: $3.76 $0.00
Disclosure

SEC source: 0001562180-24-002771 · primarydocument.xml · derivative · entry 3

Mills Kenneth T. · CIK 0001652824 · Director · President and CEO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 111,354

Underlying: Common Stock · 15,000 shares

Expires 2025-05-19

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan.

F3 · derivative.exercise_date: The previously granted option, which expires on May 19, 2025, representing a right to purchase a total of 275,000 shares, became exercisable as follows: 25% of the shares subject to this option vested on May 19, 2016, and the balance vested in equal monthly installments over the 36 months thereafter.

Read SEC document
March 14, 2024 Filed Mar 18, 2024 21:03 UTC REGENXBIO Inc. RGNX · Entity 2211 SaleCommon Stock 15,000 $21.86 $327,942.00
Disclosure

SEC source: 0001562180-24-002771 · primarydocument.xml · nonDerivative · entry 2

Mills Kenneth T. · CIK 0001652824 · Director · President and CEO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 408,035

F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan.

F2 · price: This transaction was executed in multiple trades at prices ranging from $21.60 to $22.31. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

Read SEC document
March 14, 2024 Filed Mar 18, 2024 21:03 UTC REGENXBIO Inc. RGNX · Entity 2211 Exercise / conversionCommon Stock 15,000 $3.76 $56,400.00
Disclosure

SEC source: 0001562180-24-002771 · primarydocument.xml · nonDerivative · entry 1

Mills Kenneth T. · CIK 0001652824 · Director · President and CEO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 423,035

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan.

Read SEC document
February 14, 2024 Filed Feb 16, 2024 23:28 UTC REGENXBIO Inc. RGNX · Entity 2211 Exercise / conversionStock Options (Right to Buy) · Derivative 15,000 $0.00 Strike: $3.76 $0.00
Disclosure

SEC source: 0001562180-24-001395 · primarydocument.xml · derivative · entry 4

Mills Kenneth T. · CIK 0001652824 · Director · President and CEO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 126,354

Underlying: Common Stock · 15,000 shares

Expires 2025-05-19

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan.

F4 · derivative.exercise_date: The previously granted option, representing a right to purchase a total of 275,000 shares, became exercisable as follows: 25% of the shares subject to this option vested on May 19, 2016, and the balance vested in equal monthly installments over the 36 months thereafter.

Read SEC document
February 14, 2024 Filed Feb 16, 2024 23:28 UTC REGENXBIO Inc. RGNX · Entity 2211 SaleCommon Stock 10,348 $16.88 $174,722.88
Disclosure

SEC source: 0001562180-24-001395 · primarydocument.xml · nonDerivative · entry 3

Mills Kenneth T. · CIK 0001652824 · Director · President and CEO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 408,035

F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan.

F3 · price: This transaction was executed in multiple trades at prices ranging from $16.78 to $17.25. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

Read SEC document
February 14, 2024 Filed Feb 16, 2024 23:28 UTC REGENXBIO Inc. RGNX · Entity 2211 SaleCommon Stock 4,652 $16.47 $76,625.88
Disclosure

SEC source: 0001562180-24-001395 · primarydocument.xml · nonDerivative · entry 2

Mills Kenneth T. · CIK 0001652824 · Director · President and CEO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 418,383

F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan.

F2 · price: This transaction was executed in multiple trades at prices ranging from $15.78 to $16.77. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

Read SEC document
February 14, 2024 Filed Feb 16, 2024 23:28 UTC REGENXBIO Inc. RGNX · Entity 2211 Exercise / conversionCommon Stock 15,000 $3.76 $56,400.00
Disclosure

SEC source: 0001562180-24-001395 · primarydocument.xml · nonDerivative · entry 1

Mills Kenneth T. · CIK 0001652824 · Director · President and CEO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 423,035

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan.

Read SEC document
January 16, 2024 Filed Jan 18, 2024 23:39 UTC REGENXBIO Inc. RGNX · Entity 2211 Exercise / conversionStock Options (Right to Buy) · Derivative 45,000 $0.00 Strike: $3.76 $0.00
Disclosure

SEC source: 0001562180-24-000544 · primarydocument.xml · derivative · entry 3

Mills Kenneth T. · CIK 0001652824 · Director · President and CEO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 141,354

Underlying: Common Stock · 45,000 shares

Expires 2025-05-19

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan.

F3 · derivative.exercise_date: The previously granted option, representing a right to purchase a total of 45,000 shares, became exercisable as follows: 25% of the shares subject to this option vested on May 19, 2015, and the balance vested in equal monthly installments over the 36 months thereafter.

Read SEC document
January 16, 2024 Filed Jan 18, 2024 23:39 UTC REGENXBIO Inc. RGNX · Entity 2211 SaleCommon Stock 45,000 $15.18 $682,992.00
Disclosure

SEC source: 0001562180-24-000544 · primarydocument.xml · nonDerivative · entry 2

Mills Kenneth T. · CIK 0001652824 · Director · President and CEO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 408,035

F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan.

F2 · price: This transaction was executed in multiple trades at prices ranging from $14.52 to $15.51. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

Read SEC document
January 16, 2024 Filed Jan 18, 2024 23:39 UTC REGENXBIO Inc. RGNX · Entity 2211 Exercise / conversionCommon Stock 45,000 $3.76 $169,200.00
Disclosure

SEC source: 0001562180-24-000544 · primarydocument.xml · nonDerivative · entry 1

Mills Kenneth T. · CIK 0001652824 · Director · President and CEO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 453,035

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan.

Read SEC document
January 02, 2024 Filed Jan 4, 2024 21:07 UTC REGENXBIO Inc. RGNX · Entity 2211 GrantStock Options (Right to buy) · Derivative 305,250 $0.00 Strike: $18.34 $0.00
Disclosure

SEC source: 0001562180-24-000223 · primarydocument.xml · derivative · entry 3

Mills Kenneth T. · CIK 0001652824 · Director · President and CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 305,250

Underlying: Common Stock · 305,250 shares

Expires 2034-01-02

F3 · derivative.exercise_date: 25% of the shares subject to this option shall vest after 12 months of continuous service with the Issuer. The balance will vest in equal monthly installments over the 36 months following January 2, 2025 while the optionee provides continuous service to the Issuer.

Read SEC document
January 02, 2024 Filed Jan 4, 2024 21:07 UTC REGENXBIO Inc. RGNX · Entity 2211 GrantCommon Stock 64,103 $0.00 $0.00
Disclosure

SEC source: 0001562180-24-000223 · primarydocument.xml · nonDerivative · entry 2

Mills Kenneth T. · CIK 0001652824 · Director · President and CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 408,035

F2 · shares: Represents shares of common stock underlying a time-based restricted stock unit award (RSU). 25% of the shares subject to this RSU will vest on each of January 1, 2025, January 1, 2026, January 1, 2027 and January 1, 2028 while the recipient provides continuous service to the Issuer.

Read SEC document
January 02, 2024 Filed Jan 4, 2024 21:07 UTC REGENXBIO Inc. RGNX · Entity 2211 Tax withholdingCommon Stock 11,357 $17.95 $203,858.15
Disclosure

SEC source: 0001562180-24-000223 · primarydocument.xml · nonDerivative · entry 1

Mills Kenneth T. · CIK 0001652824 · Director · President and CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 343,932

F1 · shares: Represents shares of common stock withheld to pay taxes upon the vesting of restricted stock units originally granted to the reporting person on January 4, 2021, January 3, 2022 and January 3, 2023. The number of shares withheld was determined on January 2, 2024 based on the closing price of the issuer's common stock on December 29, 2023.

Read SEC document
December 19, 2023 Filed Dec 21, 2023 18:38 UTC REGENXBIO Inc. RGNX · Entity 2211 Exercise / conversionStock Options (Right to Buy) · Derivative 1,500 $0.00 Strike: $0.85 $0.00
Disclosure

SEC source: 0001562180-23-008519 · primarydocument.xml · derivative · entry 5

Mills Kenneth T. · CIK 0001652824 · Director · President and CEO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 36,316

Underlying: Common Stock · 1,500 shares

Expires 2024-09-24

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan.

F4 · derivative.exercise_date: The previously granted option, representing a right to purchase a total of 1,500 shares, became exercisable as follows: 25% of the shares subject to this option vested on September 24, 2015, and the balance vested in equal monthly installments over the 36 months thereafter.

Read SEC document
December 19, 2023 Filed Dec 21, 2023 18:38 UTC REGENXBIO Inc. RGNX · Entity 2211 Exercise / conversionStock Options (Right to Buy) · Derivative 43,500 $0.00 Strike: $3.76 $0.00
Disclosure

SEC source: 0001562180-23-008519 · primarydocument.xml · derivative · entry 4

Mills Kenneth T. · CIK 0001652824 · Director · President and CEO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 186,354

Underlying: Common Stock · 43,500 shares

Expires 2025-05-19

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan.

F3 · derivative.exercise_date: The previously granted option, representing a right to purchase a total of 43,500 shares, became exercisable as follows: 25% of the shares subject to this option vested on May 9, 2016, and the balance vested in equal monthly installments over the 36 months thereafter.

Read SEC document
December 19, 2023 Filed Dec 21, 2023 18:38 UTC REGENXBIO Inc. RGNX · Entity 2211 SaleCommon Stock 45,000 $19.69 $885,825.00
Disclosure

SEC source: 0001562180-23-008519 · primarydocument.xml · nonDerivative · entry 3

Mills Kenneth T. · CIK 0001652824 · Director · President and CEO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 355,289

F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan.

F2 · price: This transaction was executed in multiple trades at prices ranging from $19.48 to $20.12. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

Read SEC document
December 19, 2023 Filed Dec 21, 2023 18:38 UTC REGENXBIO Inc. RGNX · Entity 2211 Exercise / conversionCommon Stock 1,500 $0.85 $1,275.00
Disclosure

SEC source: 0001562180-23-008519 · primarydocument.xml · nonDerivative · entry 2

Mills Kenneth T. · CIK 0001652824 · Director · President and CEO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 400,289

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan.

Read SEC document
December 19, 2023 Filed Dec 21, 2023 18:38 UTC REGENXBIO Inc. RGNX · Entity 2211 Exercise / conversionCommon Stock 43,500 $3.76 $163,560.00
Disclosure

SEC source: 0001562180-23-008519 · primarydocument.xml · nonDerivative · entry 1

Mills Kenneth T. · CIK 0001652824 · Director · President and CEO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 398,789

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan.

Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.